🇺🇸 Sulfamethoxazole Trimethoprim Combination in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 14

Most-reported reactions

1. Pyrexia — 3 reports (21.43%)
2. Neutropenia — 2 reports (14.29%)
3. Pneumocystis Jirovecii Pneumonia — 2 reports (14.29%)
4. Abdominal Pain — 1 report (7.14%)
5. Balance Disorder — 1 report (7.14%)
6. Blood Pressure Decreased — 1 report (7.14%)
7. C-Reactive Protein Increased — 1 report (7.14%)
8. Cytomegalovirus Infection — 1 report (7.14%)
9. Cytomegalovirus Viraemia — 1 report (7.14%)
10. Depressed Level Of Consciousness — 1 report (7.14%)

Source database →

Frequently asked questions

Is Sulfamethoxazole Trimethoprim Combination approved in United States?

Sulfamethoxazole Trimethoprim Combination does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sulfamethoxazole Trimethoprim Combination in United States?

Baylor Research Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.